COVID-19 Immune Repertoire Sequencing

Institute of Tropical Medicine, Belgium84 enrolled

Overview

This concerns a single-center prospective interventional cohort study. Laboratory-confirmed COVID-19 patients will be asked to donate blood at at least two different timepoints. This will allow us to investigate T and B cell evolutions during the course of infection and recovery. The expected duration of the study is four months or the total duration of the SARS-CoV-2 circulation in Belgium (whichever is shortest).

Study Type

OBSERVATIONAL

Enrollment

Conditions

COVID SARS-CoV 2 Corona Virus Infection RDT B Cell

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * laboratory confirmed COVID-19 acute infection * be older than 18 years of age * be hospitalized at the UZA * willing and able to provide written informed consent by the participant or its legal representative (for instance in case of medical incapacitation) Exclusion Criteria: * younger than 18 years old * Ambulatory patients

Locations (1)

Universitairy hospital of Antwerp

Antwerp, Belgium

Outcomes

Primary Outcomes

provide proof-of-concept that (longitudinal) B cell repertoire mining allows identification of emerging virus specific B cell receptor variable regions.

Time frame: 4 months

Secondary Outcomes

study evolutions in B and T cell repertoires to understand COVID-19 specific immune responses fundamentally.

Time frame: every 7 days during hospitalization a bloodsample is taken

clinical and epidemiological description of UZA hospitalized COVID-19 patients

Time frame: at hospitalization

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.